Aurora Cannabis (ACB) vs Akebia Therapeutics (AKBA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Aurora Cannabis (ACB) has outperformed Akebia Therapeutics (AKBA) over the past year, losing 27.7% versus a loss of 70.4%. Over five years, AKBA leads with a -69.4% price change compared with -93.7% for ACB. Aurora Cannabis is the larger company by market cap ($282.4 million vs $242.0 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ACB | AKBA |
|---|---|---|
| Share price | $4.46 | $0.8734 |
| Market cap | $282.36M | $242.02M |
| 1-day change | -2.83% | -0.58% |
| YTD return | +5.69% | -45.75% |
| 1-year return | -27.71% | -70.39% |
| 5-year return | -93.66% | -69.35% |
| EPS (TTM) | $-0.59 | $-0.12 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $6.67 | $3.20 |
| 52-week low | $2.56 | $0.814 |
| Distance from 52-week high | -33.08% | -72.71% |
| Analyst consensus | buy | none |
| Avg. price target upside | — | +348.82% |
| Average volume | 1.36M | 6.09M |
| Shares outstanding | 63.31M | 277.11M |
| Employees | 1,028 | 194 |
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic | Drug Manufacturers - Specialty & Generic |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ACB has outperformed AKBA by 42.7 percentage points over the past year.
About Aurora Cannabis
ACB stock →Aurora Cannabis Inc., together with its subsidiaries, engages in the production, distribution, and sale of cannabis products in Canada and internationally. The company offers pharmaceutical-grade cannabis products; and medical and consumer cannabis products.
Healthcare · Drug Manufacturers - Specialty & Generic · 1,028 employees
About Akebia Therapeutics
AKBA stock →Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD and the treatment of iron deficiency anemia in adult patients with NDD-CKD.
Healthcare · Drug Manufacturers - Specialty & Generic · 194 employees
ACB vs AKBA FAQ
Which is bigger, Aurora Cannabis or Akebia Therapeutics?
Aurora Cannabis (ACB) is larger, with a market capitalization of $282.36M compared with $242.02M for Akebia Therapeutics (AKBA).
Which stock has performed better over the past year, ACB or AKBA?
ACB returned -27.71% over the past 12 months, compared with -70.39% for AKBA (price return, excluding dividends). Past performance does not predict future results.
Are Aurora Cannabis and Akebia Therapeutics in the same industry?
Yes. Both are classified in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector.